Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

Inclusion Criteria: * Written informed consent provided. * Unresectable stage III non-small cell lung cancer confirmed by histopathology or cytology. * ECOG score is 0 or 1. * Adequate hematological function, liver function and renal function. Exclusion Criteria: * Previously received systemic anti-tumor therapy for non-small cell lung cancer. * history or current (non-infectious) pneumonia/interstitial pneumonia requiring steroid treatment. * History or active pulmonary tuberculosis. * Active infections that require systemic treatment. * History or suspected autoimmune disease or immune deficiency who, in the judgment of the investigator, cannot tolerate immunotherapy. * Untreated active Hepatitis B. * Has a known history of human immunodeficiency virus (HIV) infection (HIV 1/2 antibody positive). * Grade 3 or above peripheral neuropathy. * Severe allergic history to pemetrexed, paclitaxel, albumin-bound paclitaxel, carboplatin or other preventive drugs. * Underlying severe or uncontrolled disease. * Malignant tumors other than NSCLC within 5 years. * Any medical condition requiring systemic treatment with corticosteroids (prednisone or equivalent at a dose of \>10mg/ day) or other immunosuppressive agents within 14 days prior to treatment.